Articles tagged with Molecular Imaging
A study using PET imaging reveals that women with the ApoE 4 allele are more susceptible than men to tau accumulation in the brain. The study also found that sex modulates the effect of ApoE ε4 on brain tau depositing in individuals with mild cognitive impairment.
A new class of radiopharmaceuticals, named radiohybrids (rh), has been developed for cancer imaging and radioligand therapy (theranostics). These rhPSMA-ligands have a unique feature that both fluorine and the metal are always present, but only one of them is present as a radioactive isotope.
A study found that PET/CT imaging can identify diseased areas in patients with extra-pulmonary tuberculosis, guiding personalized therapy. The test provides a whole-body survey, helping to estimate disease extent and predict treatment response.
Di Carli is recognized as an outstanding clinician-scientist, teacher, and mentor, known for pioneering work in cardiovascular radionuclide imaging and services. His research has contributed to understanding ischemic cardiac dysfunction and using positron emission tomography (PET) for guiding management of patients with end-stage heart...
A first-in-human Phase 1/Phase II study demonstrates the safety and efficacy of intravenous administration of technetium-99m tilmanocept for monitoring rheumatoid arthritis disease activity. The imaging agent binds to activated macrophages, providing joint-specific information on RA disease involvement.
Jason S. Lewis, PhD, has received the 2019 Paul C. Aebersold Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to basic nuclear medicine science. His research focuses on developing radiopharmaceuticals for targeted diagnosis and treatment of cancer.
Researchers developed a new type of nuclear medicine scan that quickly and precisely diagnoses inflammation in IBD using monoclonal antibodies directed against specific innate immune cell markers. The immuno-PET scan has high potential for theranostic diagnosis and precision treatment of IBD and other inflammatory diseases.
A multicenter study found that deep learning analysis of single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) improved the diagnosis of obstructive coronary artery disease. The new method showed increased sensitivity and accuracy compared to traditional methods, leading to better patient outcomes.
A 12-year retrospective clinical study shows the long-term effectiveness of PRRT, allowing patients to maintain a high quality of life. The overall response rate is about 70-80 percent, and prognosis is generally favorable for patients who respond to therapy.
The first total-body PET/CT scanner has shown promising results in enhancing image quality, reducing scan time, and lowering dose. Clinical trials have demonstrated improved diagnostic capabilities with minimal impact on patient exposure.
Researchers have identified two new nuclear medicine tracers that provide high-contrast images for cancer diagnosis, allowing for shorter imaging times and no diet changes. The tracers target cancer-associated fibroblasts, promoting tumor growth, migration, and progression.
Researchers have developed a novel PET/CT tracer that detects and characterizes blood clots in the legs, where conventional imaging has limitations. The new imaging agent may provide more accurate diagnoses and information on clot growth or embolization, leading to changes in clinical intervention.
Researchers have found that a new PET imaging agent, 18F-FFNP, can measure changes in progesterone receptor levels resulting from hormone therapy for breast cancer patients. This could provide an earlier indicator of therapy effectiveness and inform individualized treatment decisions.
A new PET probe targets melanin pigment in skin cancer lesions to improve detection of primary and metastatic melanoma. The probe shows promising results in clinical trials, outperforming existing methods like 18F-FDG PET/CT scans.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
A new second-generation positron emission tomography (PET) tracer has been identified for imaging tau pathology in Alzheimer's disease patients. The tracer, 18F-RO-948, showed promising results in a human evaluation study, outperforming other novel tau-specific radiopharmaceuticals.
Researchers developed a novel SPECT tracer to image c-Met expression in NSCLC, producing clearer images in less time and reducing radiation exposure. The tracer showed high specificity and rapid clearance from the body, making it potentially suitable for clinical use.
Researchers developed a hybrid nanoplatform that locates tumors using three different types of contrast simultaneously, facilitating multimodal molecular medical imaging. The platform overcomes the limitations of single image modality while maximizing their advantages.
A new preclinical study shows that PET imaging with the 18F-FAC radiotracer can image T cells in the liver, potentially reducing biopsies and improving treatment. The approach could lead to personalized treatment of patients with immune-related liver disease.
A new PET imaging radiotracer, <sup> 18 </sup> F-XTRA, was tested on adults to study the distribution of the α4β2 nicotinic acetylcholine receptor in the brain. The research found that the radiotracer rapidly entered the brain and distributed quickly, with lower binding in the hippocampus with healthy aging.
Dr. Robert Gillies, chair of Cancer Physiology and Radiology Research at Moffitt Cancer Center, receives the World Molecular Imaging Society's Gold Medal Award for his lifetime research in molecular imaging. His work focuses on understanding cancers as complex systems, leading to new cancer treatment options.
A recent study highlights the potential for misinterpretation of Prostate-Specific Membrane Antigen (PSMA) PET results, which can affect diagnostic accuracy and guide therapy. Researchers urge nuclear medicine physicians to analyze PSMA-ligand uptake in conjunction with lesion localization to avoid misdiagnosis.
Researchers used a PET tracer to identify differences in ER expression across metastases and surrounding normal tissue in breast cancer patients. The study found that approximately 50% of patients had one or more estrogen-receptor negative lesions, highlighting the heterogeneity of ER expression.
Researchers have developed a novel PET imaging method that can measure beta-cell mass, enhancing the ability to monitor and guide diabetes therapies. The new imaging method uses a radioligand to identify beta cells and has shown promising results in differentiating between healthy individuals and those with type 1 diabetes.
The Society of Nuclear Medicine and Molecular Imaging's Technologist Section recognized contributions from April Mann, Cybil Nielsen, Cheryl Rickley, and Lynne Roy for their dedication to advancing nuclear medicine technology. The awards highlight the impact of these individuals on education, advocacy, and service in the field.
The Journal of Nuclear Medicine's impact factor increased by 12% in 2017, ranking fifth among medical imaging journals. Citations to the journal rose from 24,977 to 27,101.
A novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers demonstrated non-toxicity to the kidneys and improved survival in mice. The treatment delivered an absorbed dose to tumors that exceeded the dose to critical organs.
The Society of Nuclear Medicine and Molecular Imaging's 65th Annual Meeting showcased advancements in theranostics, quantitative nuclear imaging, and multimodality molecular imaging. Key findings include improved diagnostic accuracy and treatment options for various diseases, highlighting the potential for precision health.
Researchers found improved quality of life and reduced tumor spread in patients treated with LuPSMA therapy. PSMA PET imaging demonstrated exceptional responses, correlating with significant reductions in PSA levels.
A study presented at the SNMMI Annual Meeting found that early treatment of advanced prostate cancer with lutetium-177 radioligand therapy can significantly prolong life, with a median overall survival of 27 months. Patients who received first-line therapy also had the longest survival rates.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the selection of 14 new Fellows, recognizing their excellence in volunteer service, scientific discovery, and clinical practice. The SNMMI Fellowship is one of the most prestigious formal recognitions available to long-time members.
A clinical trial found that 59% of patients with biochemical recurrence of prostate cancer had their clinical management changed by fluciclovine PET/CT imaging. The study detected disease in the prostate, pelvic lymph nodes, and less commonly, bone, guiding treatment decisions for men with recurrent prostate cancer.
A novel intelligent theranostic agent was designed to target tumors, with the ability to self-assemble in the tumor microenvironment and activate for therapy guided by photoacoustic imaging. The clusters showed high selectivity to the tumor microenvironment and eliminated tumor growth without subsequent recurrence.
Gambhir's work on multimodality molecular imaging has advanced nuclear medicine and healthcare. He has developed strategies to study gene and cell therapies, and his lab has more than 625 publications and over 40 patents pending.
Researchers have developed a novel approach to pretargeted radioimmunotherapy, which has shown complete responses in several solid tumor types using the beta-emitting lutetium-177 and alpha-emitting actinium-225. The new approach offers greater versatility of treatment for various solid tumors and clinical situations.
A new molecular imaging method allows early assessment of gene therapy success, potentially improving treatment for Parkinson's and Alzheimer's diseases. The PET reporter gene/probe system enables noninvasive monitoring of gene expression in all brain areas.
A new long-lasting type of radionuclide therapy has been proven effective in treating advanced neuroendocrine tumors, with the treatment lasting up to 4 times longer than previous options. The therapy, Lutathera-177 (Lu-DOTA-EB-TATE), was well-tolerated and showed promising results in a Phase I trial.
Richard L. Wahl, MD, has been recognized for his pioneering work in radioimmunotherapy, PET scans, and fusion imaging. His research has significantly contributed to understanding cancer prognosis, treatment response, and the importance of metabolic activity.
Simon Cherry has made significant contributions to biomedical imaging instrumentation and technology development, including microPET and hybrid PET/MRI systems. He is widely recognized for his work on molecular imaging and has received numerous awards for his achievements.
Researchers have developed a novel nuclear medicine probe that can detect synaptic density loss in the brain, a key biomarker for neurodegenerative diseases like Alzheimer's. The probe, using positron emission tomography (PET) imaging, has high imaging characteristics and is suitable for clinical trials and commercialization.
Researchers have demonstrated that combining targeted radionuclide therapy with immunotherapy can enhance treatment response and lead to a high cure rate in melanoma patients. This novel approach uses yttrium-86 (Y-86) NM600, which selectively targets tumors and delivers precise radiation doses.
A novel PET tracer has been developed to accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The tracer, called 6'-[18F]Fluoromaltotriose, is transported into bacterial cells by a membrane transport system exclusive to bacteria, allowing for specific imaging of bacterial infections.
Researchers developed a novel PSMA-targeting agent by conjugating MCG with an albumin-binding Evans blue derivative, improving tumor delivery and increasing the therapeutic effect. The agent showed significant tumor growth inhibition and complete eradication of tumors in mice, suggesting a promising strategy for cancer management.
A novel PET imaging method uses antibody fragment probes to target immune cells, detecting inflammation in the bowel and potentially guiding biopsies. The technique has wide applications in various diseases and could unlock assessment of inflammation.
Researchers developed a DOTA-conjugated NTR1 antagonist to treat and monitor pancreatic cancer, showing significant tumor growth inhibition in early studies. The novel procedure was well-tolerated by patients, with one experiencing improved symptoms and quality of life.
A new PET tracer has shown potential in predicting treatment effectiveness for depression by measuring the level of serotonin transporter protein in the brain. The study found that patients who responded to treatment had lower levels of this protein before treatment began, suggesting a biomarker for remission.
Researchers have developed a new PET imaging agent that targets NMDA receptors in nerve cells to assess treatments for various neurological diseases. The agent, C-Me-NB1, provides valuable insights into the role of NMDA receptors in brain disorders.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
Researchers developed a new approach that uses a single PET scan to assess PD-L1 positive tumors, enabling personalized cancer treatment. The study demonstrates the feasibility of this non-invasive method, which may help guide treatment decisions and assess treatment response.
The new TILT3D microscope produces clear 3-D images of structures and individual molecules within a cell, overcoming existing illumination techniques' limitations. Researchers can track the 3-D movement of molecules over time with high precision, enabling detailed studies of cellular structures.
The Society of Nuclear Medicine and Molecular Imaging and the American Society of Nuclear Cardiology have issued joint guidelines for the clinical quantification of myocardial blood flow using Positron Emission Tomography (PET). The guidelines provide a comprehensive framework for the measurement and interpretation of myocardial blood ...
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.
PSMA PET/CT detects prostate cancer recurrence earlier than current imaging modalities, enabling more effective salvage radiotherapy. Nearly half of patients with biochemical recurrence show positive results, with lesions often found in bone and perirectal lymph nodes.
The new total-body PET/CT scanner will advance clinical research and patient care by providing better imaging data from the whole body, reducing radiation exposure and increasing sensitivity. This technology has the potential to change cancer detection and staging methods, as well as improve diagnosis for other systemic conditions.
A new PET tracer has been developed to effectively gauge the effectiveness of promising Alzheimer's treatments in mouse models. The tracer binds to BACE1, a key enzyme involved in amyloid-β development, and accurately measures its effects on brain metabolism, neuroinflammation, and amyloid-β pathology.
A new sensor molecule allows researchers to visualize calcium concentrations in living animals without genetic modification or radiation exposure. This breakthrough enables better understanding of disease processes and has potential applications in improving medical treatments.
INRS professors François Légaré and Federico Rosei have been elected OSA Fellows for their groundbreaking work in ultrafast molecular imaging and photonic materials development. The distinction reflects their leadership, publication record, and significant impact on optics and photonics research.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT imaging in cancer patients. The AUC aims to improve the utilization of this technology and provide guidance for providers across specialties.
Researchers report on a new dosing regimen for actinium-225 labeled targeted alpha therapy, showing promising anti-tumor response in patients with PSMA-positive tumors. The treatment protocol balances treatment response with toxicity concerns to provide effective therapy with minimal side effects.
Theranostics combines predictive biomarkers and precise therapy to target cancer cells, minimizing side effects. The field is expected to change nuclear medicine from 'nuclear radiology' to true 'nuclear medicine,' with potential for cures.